About Us

About Us

Company Profile

Great Bay Bio (GBB), headquartered in Hong Kong, was founded in 2019 with extensive footprint in the Greater Bay Area. Adhering to the corporate vision of “Global Bioprocessing Made Simpler and More Efficient", GBB is committed to applying AI and other cutting-edge technologies to promote bioprocessing innovations, thus solve pain points, such as long timelines, high cost and low success rate, in drug development. GBB takes improving human life, health and value as its long-term goal.

The core team of GBB is composed of global talents with expertise in medicine, pharmacy, synthetic biology and AI. With a 3000 m2 R&D center and CMC platform, GBB has successfully pushed several biological drugs into the NDA stage, including national class 1 new drugs. During the three years since its establishment, GBB has applied for more than 30 patents for its AI empowered bioprocesses solutions. The resulting AI platforms were successfully commercialized, enabling GBB to establish long-term cooperation with many domestic and foreign leading enterprises.

GBB has attained the titles of National “High-Tech Enterprise” twice in a row by the National High-Tech Enterprise Certification Management Leading Group Office, “Sprouts List Most Valuable Enterprises for Investment in China for the Year 2020” by the Zero2IPO Group, “Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2020” by ZDVC RESEARCH and KPMG China, “Top 15 in the 2021 Merck Greater Bay Area Innovation Bootcamp” and “Spring class of Microsoft accelerator entrepreneurship acceleration plan in 2022”.


Forged Strategic Alliance with Cheerland Life Science.

Forged Strategic Alliance with ChemPartner.

GBB Successfully Joined NVIDIA's Inception Program and Won the Special Prize of NVIDIA Start-up Final Presentation.

Completed Series A Fundraising Worth of Nearly USD 10M.

Awarded the Gen.T Social Impact and Leader of Tomorrow 2021.

Entered Top 15 of 2021 Merck Greater Bay Area Innovation Bootcamp.

Entered Hong Kong Science Park.

Forged Strategic Alliance with Chime Biologics.

Launched AI-enabled Cell Line Stability Prediction Platform, AlfaStaX®.

Launched AI-enabled Cell Culture Media Development Platform, AlfaMedX®.

Completed USD 3.8M Convertible Note Financing  Led by Alibaba Hong Kong Entrepreneurs Fund.


Launched AI-enabled Site-Specific Integration Cell Line Development Platform, AlfaCell®.

Landed USD 15M Pre-Series B Funding Led by Tiger Jade Capital.

Listed on 2022 Spring Semester of Microsoft Acceleration Program.


R&D Experimental Center


Biology-related Patents


IND Projects


Al-related Patents


GBB Clients